[1] TAN X,LETENDRE JH,COLLINS JJ,et al.Synthetic biology in the clinic:engineering vaccines,diagnostics,and therapeutics[J].Cell,2021,184(4):881-898.
[2] MADHUSOODANAN J.News feature:editing the microbiome[J].Proc Natl Acad Sci USA,2020,117(7):3345-3348.
[3] WOELK CH,SNYDER A.Modulating gut microbiota to treat cancer[J].Science,2021,371(6529):573-574.
[4] ZHOU SB,GRAVEKAMP C,BERMUDES D,et al.Tumour-targeting bacteria engineered to fight cancer[J].Nat Rev Cancer,2018,18(12):727-743.
[5] RIEMER AB.Bacterial peptides presented on tumour cells could be immunotherapy targets[J].Nature,2021,592(7852):28-29.
[6] ALDERTON G.Synthetic bacterial cancer therapy[J].Science,2019,365(6452):459-460.
[7] FAN C,DAVISON PA,HABGOOD R,et al.Chromosome-free bacterial cells are safe and programmable platforms for synthetic biology[J].Proc Natl Acad Sci USA,2020,117(12):6752-6761.
[8] XIE M,FUSSENEGGER M.Designing cell function:assembly of synthetic gene circuits for cell biology applications[J].Nat Rev Mol Cell Biol,2018,19(8):507-525.
[9] SEDLMAYER F,AUBEL D,FUSSENEGGER M.Synthetic gene circuits for the detection,elimination and prevention of disease[J].Nat Biomed Eng,2018,2(6):399-415.
[10] NISSIM L,WU MR,PERY E,et al.Synthetic RNA-based immunomodulatory gene circuits for cancer immunotherapy[J].Cell,2017,171(5):1138-1150.
[11] WEBER EW,MAUS MV,MACKALL CL.The emerging landscape of immune cell therapies[J].Cell,2020,181(1):46-62.
[12] HAMILTON JR,DOUDNA JA.Knocking out barriers to engineered cell activity[J].Science,2020,367(6481):976-977.
[13] SINGH AK,MCGUIRK JP.CAR T cells:continuation in a revolution of immunotherapy[J].Lancet Oncol,2020,21(3):e168-e178.
[14] WU MR,JUSIAK B,LU TK.Engineering advanced cancer therapies with synthetic biology[J].Nat Rev Cancer,2019,19(4):187-195.
[15] LUSSIER F,STAUFER O,PLATZMAN I,et al.Can bottom-up synthetic biology generate advanced drug-delivery systems[J].Trends Biotechnol,2021,39(5):445-459.
[16] NOZAKI T,KANAI M.Chemical catalysis intervening to histone epigenetics[J].Acc Chem Res,2021,54(9):2313-2322.
[17]TRECI ,LWER M,SCHRRS B,et al.Challenges towards the realization of individualized cancer vaccines[J].Nat Biomed Eng,2018,2(8):566-569.
[18] SAHIN U,TRECI .Personalized vaccines for cancer immunotherapy[J].Science,2018,359(6382):1355-1360.
[19] JANI MS,VEETIL AT,KRISHNAN Y.Precision immunomodulation with synthetic nucleic acid technologies[J].Nature Reviews Materials,2019,4:451-458.
[20] SILVA DA,YU S,ULGE UY,et al.De novo design of potent and selective mimics of IL-2 and IL-15[J].Nature,2019,565(7738):186-191.
[21] PIFFERI C,FUENTES R,FERNNDEZ-TEJADA A.Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action[J].Nat Rev Chem,2021,25:1-20.
[22] GUJAR S,BELL J,DIALLO JS.SnapShot:Cancer immunotherapy with oncolytic viruses[J].Cell,2019,176(5):1240.
[23] BLASS E,OTT PA.Advances in the development of personalized neoantigen-based therapeutic cancer vaccines[J].Nat Rev Clin Oncol,2021,18(4):215-229.
[24] CHEN Z,ELOWITZ MB.Programmable protein circuit design[J].Cell,2021,184(9):2284-2301.